GPT and Oligomenorrhea: In participants who received SHR7280, the most common treatment-related AEs were oligomenorrhoea (95.0% [38/40] with SHR7280 vs. 0 with placebo), increased alanine aminotransferase (20.0% [8/40] vs. 25.0% [2/8]), and increased blood thyroid stimulating hormone (15.0% [6/40] vs. 0).